recurrence rates. In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. Methods Literature Search Strategy The authors searched the Cochrane Controlled Trials Register (CENTRAL
Search Results
Perioperative Intravesical Chemotherapy in Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman
HSR22-170: Risk Factors for 30-Days Readmission in Pancreatic Cancer With Hospice
Paramveer Singh, Jasmeet Kaur, Tanvir Mir, Yaqub Nadeem, Marukh Khalid, and Rafiullah Khan
risk factors are associated with hospice patients' readmissions. This study aims to identify predictors of 30-day readmission and incidence of in-hospital mortality in hospice patients with PAC. Methods : A retrospective study of a nationally
A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status
Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey
-intent resection of CLM, it is critical to explore this issue further and develop a potential surveillance algorithm specific to this patient cohort. Within this context, the primary aim of this study was to assess the changes in recurrence risks and risk factors
CLO24-076: Prolonged Anesthesia as a Risk Factor for Extended Length of Stay Following Craniotomy for Primary Glioma
Samantha Schimmel, Jonah Gordon, Adam Alayli, Gavin Lockard, Anshruta Dhanashekar, Vishnu V. Iyer, Bassel El Sayed, Samuel Bauserman, Nasrin Aldawoodi, Allan Escher, Rahul Mhaskar, and Nam D. Tran
Background: Extended length of surgery is a well-established risk factor for increased hospital length of stay (LOS) and emerging data suggests that prolonged anesthesia may also influence LOS. The effects of anesthesia duration and select
CLO21-016: Incidence, Risk Factors, and Prognostic Implications of Peri-Transplant Orthostatic Hypotension in Patients With Multiple Myeloma
Matthew Ho, Maria Moscvin, Soon Khai Low, Sara Close, Robert Schlossman, Jacob Laubach, Brett Glotzbecker, Paul Richardson, and Giada Bianchi
to severe dehydration as defined by weight loss ≥ 5% body weight, suggesting OH could not be simply be explained by volume depletion. Multivariable analysis revealed three risk factors (white race, gabapentin, antihypertensives) and two protective
Complications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemia
Ruben Niesvizky and Ashraf Z. Badros
preventing, identifying, and managing them. Venous Thromboembolism VTE typically manifests as deep vein thrombosis (DVT) or pulmonary embolism (PE). Both cancer and cancer treatments have been identified as discrete risk factors. 1 Current evidence
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy
Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian
chi-square test for categorical or 2-sided Student t tests for continuous variables. Univariable Cox proportional hazards regression was used to characterize the association between patient, disease, and CAR T-cell–related risk factors and 1-year PFS
Association of Intellectual and Developmental Disabilities With Worse Outcomes After Surgical Treatment of Cancer
Vivian Resende, Selamawit Woldesenbet, Erryk Katayama, Muhammad Musaab Munir, Henrique Araújo Lima, Mujtaba Khalil, Karol Rawicz-Pruszyński, Muhammad Muntazir Mehdi Khan, Usama Waqar, Parit Mavani, Yutaka Endo, and Timothy M. Pawlik
Table S2 ). Table 2. Multivariable Analysis of Surgical Outcomes for Patients With IDD, Adjusted for Competing Risk Factors Long-Term Survival Median overall survival was 49.7 months (95% CI, 49.5–50.0 months) in the cohort. Patients with
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde
Rasha Abo El Hassan, Noura Anwar Abdel-Fatah, Hadeer Khalefa Ahmed, May Shawki, and Lamia El Wkeel
risk factors for Paclitaxel induced peripheral neuropathy (PIPN). Methods : NCT03492047 is prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m2 weekly for 12 weeks
CLO24-066: Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non–Small Cell Lung Cancer: Risk Factors Associated With Mortality
Cesar Simbaqueba Clavijo, Mehmet Altan, Maria Franco-Vega, Melvin Rivera, and Anisha Patel
medical record review. A survival analysis was conducted with Kaplan Meier estimates, a Cox proportional univariate regression was done with all variable risk factors, and a multivariable Cox regression analysis were done with those risk factor variables